9H-indeno[2,1-d]pyrimidine | 25459-48-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 9H-indeno[2,1-d]pyrimidine
• 英文别名: Indenopyrimidine；9H-indeno[2,1-d]pyrimidine
• CAS: 25459-48-7
• 化学式: C₁₁H₈N₂
• mdl: MFCD18449384
• 分子量: 168.198
• InChiKey: KPXWJZVFWZHULA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME
  申请人：Samsung Display Co., Ltd.

  公开号：US20210057657A1

  公开（公告）日：2021-02-25

  An organometallic compound is represented by Formula 1. An organic light-emitting device includes: a first electrode; a second electrode facing the first electrode; an organic layer between the first electrode and the second electrode and comprising an emission layer; and the organometallic compound represented by Formula 1. In Formula 1, each substituent is the same as described herein.

  一个含有有机金属化合物的化学式为Formula 1。一种有机发光器件包括：第一电极；面向第一电极的第二电极；位于第一电极和第二电极之间的有机层，包括一个发射层；以及化学式为Formula 1的有机金属化合物。在Formula 1中，每个取代基与此处描述的相同。
• ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING ORGANOMETALLIC COMPOUND
  申请人：SAMSUNG ELECTRONICS CO., LTD.

  公开号：US20180130964A1

  公开（公告）日：2018-05-10

  An organometallic compound represented by Formula 1: wherein, in Formula 1, groups and variables are the same as described in the specification.

  一个由化学式1表示的有机金属化合物：其中，在化学式1中，基团和变量与规范中描述的相同。
• Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents
  申请人：Duquesne University of the Holy Spirit

  公开号：US20160304525A1

  公开（公告）日：2016-10-20

  The present invention provides a compound of Formula I, and salts thereof, and a pharmaceutical composition comprising a compound of Formula I: wherein R 1 is selected from the group consisting of and R 2 is an alkyl group having from one to ten carbon atoms, or wherein R 2 is selected from the group consisting of R 1 is an alkyl group having from one to ten carbon atoms; and R is H, or an alkyl group having from one to ten carbon atoms, and R 3 is H, an alkyl group having from one to ten carbon atoms, or a halogen. Preferably the compound of Formula V includes wherein R 3 is a halogen, and most preferably wherein the halogen is chlorine. Methods of treating a patient with cancer with these compounds are also provided.

  本发明提供了一种化合物I的盐，以及包括化合物I的药物组合物：其中R1选自以下组成的群体，R2是具有一到十个碳原子的烷基基团，或者R2选自以下组成的群体，R1是具有一到十个碳原子的烷基基团；R是H，或者具有一到十个碳原子的烷基基团，R3是H，具有一到十个碳原子的烷基基团，或者卤素。优选化合物V包括其中R3是卤素，最优选其中卤素是氯。还提供了使用这些化合物治疗癌症患者的方法。
• ORGANIC LIGHT-EMITTING DEVICE, APPARATUS INCLUDING THE SAME, AND ORGANOMETALLIC COMPOUND
  申请人：SAMSUNG DISPLAY CO., LTD.

  公开号：US20200099001A1

  公开（公告）日：2020-03-26

  Provided are an organic light-emitting device, an apparatus including the organic light-emitting device, and an organometallic compound represented by Formula 1. The organic light-emitting device includes: a first electrode; a second electrode; and an organic layer between the first electrode and the second electrode and including an emission layer, wherein: the organic layer includes the organometallic compound represented by Formula 1.

  提供了一种有机发光装置，包括该有机发光装置的装置，以及由化学式1表示的有机金属化合物。该有机发光装置包括：第一电极；第二电极；以及位于第一电极和第二电极之间的有机层，包括一个发射层，其中：有机层包括由化学式1表示的有机金属化合物。
• [EN] ARYLINDENOPYRIDINES AND ARYLINDENOPYRIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONIST<br/>[FR] ARYLINDENOPYRIDINES ET ARYLINDENOPYRIMIDINES ET LEUR UTILISATION EN TANT QU'ANTAGONISTE DES RECEPTEURS D'ADENOSINE A2A
  申请人：ORTHO MCNEIL PHARM INC

  公开号：WO2005042500A1

  公开（公告）日：2005-05-12

  This invention provides novel arylindenopyridines and arylindenopyrimidines of formula (I), (II) wherein R1, R2, R3, R4, and X are as defined above, and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing adenosine A2a receptors. This invention also provides therapeutic and prophylactic methods using the instant compounds and pharmaceutical compositions.

  该发明提供了新颖的芳基吲哚吡啶和芳基吲哚嘧啶，化学式为(I)、(II)，其中R1、R2、R3、R4和X如上定义，并包括同样的药物组合物，用于治疗通过拮抗腺苷A2a受体改善的疾病。该发明还提供了使用这些化合物和药物组合物的治疗和预防方法。